Payment overview · 2025
General Payments
$221.59
6 reported records · 5 companies
Healthcare provider profile · identity verified
Matthew Neil Lilly, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · MORGAN HILL, CA · NPI 1346571643
Verified facts
What the public records show
CMS Open Payments records show Matthew Neil Lilly, MD received $221.59 in general payments during 2025 across 6 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 56.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Austedo Xr, Rexulti.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Eliquis by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rexulti by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Austedo by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Austedo Xr by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UZEDY as an associated drug or biological on 46702 records involving 13355 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Uzedy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $125.64 | 56.7% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $29.86 | 13.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.58 | 11.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.41 | 9.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20.10 | 9.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Education | $111.49 | 1 |
| Food and Beverage | $110.10 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $29.86 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $25.58 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $20.10 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $14.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | UZEDY open payments reported associated product |
CMS Open Payments — General Payments 46702 supporting records · 13355 recipient NPIs · example record 1247244226 |
Uzedy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Olanzapine | Olanzapine | 624 | 43 |
| Clozapine | Clozapine | 570 | 40 |
| Quetiapine Fumarate | Quetiapine Fumarate | 306 | 28 |
| Clonazepam | Clonazepam | 295 | 32 |
| Lithium Carbonate | Lithium Carbonate | 276 | 29 |
| Levothyroxine Sodium | Levothyroxine Sodium | 255 | 30 |
| Risperidone | Risperidone | 242 | 23 |
| Benztropine Mesylate | Benztropine Mesylate | 241 | 29 |
| Gabapentin | Gabapentin | 215 | 26 |
| Atorvastatin Calcium | Atorvastatin Calcium | 210 | 32 |
| Trazodone Hcl | Trazodone Hcl | 183 | 32 |
| Aripiprazole | Aripiprazole | 170 | 20 |
| Divalproex Sodium | Divalproex Sodium | 163 | 26 |
| Clozapine Odt | Clozapine | 158 | suppressed |
| Haloperidol | Haloperidol | 157 | 15 |
| Famotidine | Famotidine | 148 | 18 |
| Invega Sustenna | Paliperidone Palmitate | 148 | 21 |
| Paliperidone Er | Paliperidone | 144 | 13 |
| Lorazepam | Lorazepam | 138 | 23 |
| Olanzapine Odt | Olanzapine | 117 | suppressed |
| Metformin Hcl | Metformin Hcl | 106 | 19 |
| Propranolol Hcl | Propranolol Hcl | 104 | 15 |
| Divalproex Sodium Er | Divalproex Sodium | 103 | 12 |
| Sertraline Hcl | Sertraline Hcl | 102 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 94 | suppressed |
| Lactulose | Lactulose | 78 | 13 |
| Bupropion Xl | Bupropion Hcl | 76 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 75 | suppressed |
| Lamotrigine | Lamotrigine | 72 | suppressed |
| Mirtazapine | Mirtazapine | 71 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 70 | suppressed |
| Risperidone Odt | Risperidone | 70 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 67 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 61 | suppressed |
| Ozempic | Semaglutide | 57 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 57 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | suppressed |
| Topiramate | Topiramate | 56 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 54 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 53 | suppressed |
| Lisinopril | Lisinopril | 51 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 48 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 46 | 12 |
| Lybalvi | Olanzapine/Samidorphan Malate | 46 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | 12 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 45 | suppressed |
| Levetiracetam | Levetiracetam | 43 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 39 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 39 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 38 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 38 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 36 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 36 | suppressed |
| Omeprazole | Omeprazole | 36 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 34 | suppressed |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Aristada | Aripiprazole Lauroxil | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 31 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 31 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 30 | suppressed |
| Rexulti | Brexpiprazole | 30 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 26 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 24 | suppressed |
| Meloxicam | Meloxicam | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Enulose | Lactulose | 21 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Furosemide | Furosemide | 19 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 19 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 18 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 18 | suppressed |
| Losartan Potassium | Losartan Potassium | 18 | suppressed |
| Caplyta | Lumateperone Tosylate | 17 | suppressed |
| Simvastatin | Simvastatin | 17 | suppressed |
| Austedo Xr | Deutetrabenazine | 16 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 16 | suppressed |
| Eliquis | Apixaban | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Lacosamide | Lacosamide | 15 | suppressed |
| Levocarnitine | Levocarnitine (With Sugar) | 15 | suppressed |
| Uzedy | Risperidone | 15 | suppressed |
| Acamprosate Calcium | Acamprosate Calcium | 14 | suppressed |
| Austedo | Deutetrabenazine | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Fanapt | Iloperidone | 14 | suppressed |
| Invega Trinza | Paliperidone Palmitate | 14 | suppressed |
| Mesalamine | Mesalamine | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Estarylla | Norgestimate-Ethinyl Estradiol | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $221.59 · 6 records | Teva Pharmaceuticals USA, Inc. | AUSTEDO XR, Auvelity, COBENFY, INGREZZA, REXULTI | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Austedo Xr play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error